 NEW YORK and SHANGHAI, China, Aug. 26, 2021 GLOBE NEWSWIRE -- BeyondSpring the Company or BeyondSpring NASDAQ: BYSI, a global pharmaceutical company focused on the development of cancer therapeutics, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. or Hengrui today announced an exclusive commercialization and co-development agreement in Greater China the Territory for BeyondSprings investigational drug candidate plinabulin, a first-in-class, selective immunomodulating microtubule-binding agent SIMBA. Plinabulin in combination with G-CSF is currently under NDA Priority Review by the U.S. Food and Drug Administration FDA and the China National Medical Products Administration NMPA for the prevention of chemotherapy-induced neutropenia CIN. BeyondSpring recently announced positive topline Phase 3 results from its DUBLIN-3 study of plinabulin in combination with docetaxel for the treatment of 2nd and 3rd line, EGFR wild-type non-small cell lung cancer NSCLC. BeyondSpring will still retain 100 of the global plinabulin rights outside of Greater China. 